Market open
Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
Website
SMMT Metrics
BasicAdvanced
$13B
-
-$0.31
-0.88
-
Price and volume
Market cap
$13B
Beta
-0.88
52-week high
$28.73
52-week low
$2.10
Average daily volume
2.4M
Financial strength
Current ratio
10.155
Quick ratio
9.895
Long term debt to equity
0.888
Total debt to equity
1.857
Interest coverage (TTM)
-24.29%
Management effectiveness
Return on assets (TTM)
-41.31%
Return on equity (TTM)
-94.90%
Valuation
Price to book
34.14
Price to tangible book (TTM)
34.14
Price to free cash flow (TTM)
-82.203
Growth
Earnings per share change (TTM)
-68.76%
3-year earnings per share growth (CAGR)
-31.41%
What the Analysts think about SMMT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
SMMT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SMMT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SMMT News
AllArticlesVideos
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Seeking Alpha·2 weeks ago
Pfizer: What The Summit Therapeutics Deal Brings
Seeking Alpha·2 weeks ago
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $13B as of March 11, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of March 11, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of March 11, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -0.88. This means that it has an inverse relation to market volatility.